Linked Data API

Show Search Form

Search Results

1108693
star this property registered interest false more like this
star this property date less than 2019-04-01more like thismore than 2019-04-01
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what discussions his Department has had with NICE on the prescription of medicinal cannabis oil for patients with (a) cerebral palsy and (b) arthritis. more like this
star this property tabling member constituency Banff and Buchan more like this
star this property tabling member printed
David Duguid more like this
star this property uin 239283 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-04-09more like thismore than 2019-04-09
star this property answer text <p>The Department has not discussed with the National Institute for Health and Care Excellence (NICE) the prescription of medicinal cannabis oil for patients with cerebral palsy and arthritis.</p><p> </p><p>NICE is the independent expert body that develops authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources. NICE is developing guidance on the prescribing of cannabis-based medicinal products by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for delivering such guidance.</p><p> </p><p>Following a public consultation on the draft scope, the guidance will focus on the use of cannabis-based products in the treatment of chronic pain, intractable nausea and vomiting, spasticity and severe treatment-resistant epilepsy, conditions where the evidence is currently most advanced. A consultation on the draft guidance is expected in the summer.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property question first answered
less than 2019-04-09T14:41:04.493Zmore like thismore than 2019-04-09T14:41:04.493Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4606
unstar this property label Biography information for David Duguid more like this
1109775
star this property registered interest false more like this
star this property date less than 2019-04-04more like thismore than 2019-04-04
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he will issue a response to Early Day Motion 1832, on legalisation of medical cannabis. more like this
star this property tabling member constituency Glasgow North more like this
star this property tabling member printed
Patrick Grady more like this
star this property uin 241057 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-04-09more like thismore than 2019-04-09
star this property answer text <p>The Government is clear that the decision to prescribe a cannabis-based product for medicinal use should only be made where it is clinically appropriate and in the best interest of the patient. This will be subject to local National Health Service governance and funding arrangements for prescribing unlicensed medicines, and patients will not be able to be prescribed such products by their general practitioner – and would require referral to a specialist clinician on the basis of clinical need.</p><p>The evidence base for cannabis-based products for medicinal use is still developing. However, the changes to the law are designed to encourage further research and the National Institute for Health Research has issued two calls for research proposals to rapidly advance knowledge in this area and remains open to research proposals outside of these calls in this priority area.</p><p>Interim clinical guidance, issued by the Royal College of Physicians, British Paediatric Neurology Association and Association of British Neurologists is based on the best available international evidence and reflects clinical guidance that has been published in other jurisdictions. This guidance will be updated and replaced in October 2019 by that commissioned from the National Institute for Health and Care Excellence.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property question first answered
less than 2019-04-09T14:40:03.737Zmore like thismore than 2019-04-09T14:40:03.737Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4432
unstar this property label Biography information for Patrick Grady more like this
1110299
star this property registered interest false more like this
star this property date less than 2019-04-08more like thismore than 2019-04-08
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, when the NICE guidance on prescribing cannabis-based products for medical use will be published. more like this
star this property tabling member constituency Liverpool, West Derby more like this
star this property tabling member printed
Stephen Twigg more like this
star this property uin 241989 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-04-11more like thismore than 2019-04-11
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is due to publish its guidelines on cannabis-based products for medicinal use in October 2019. The guidance will focus on four indications: chronic pain, intractable nausea and vomiting, treatment-resistant epilepsy and spasticity. It will be based on the best available international evidence and produced using NICE’s world-renowned process for delivering such guidelines.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property question first answered
less than 2019-04-11T16:58:48.107Zmore like thismore than 2019-04-11T16:58:48.107Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
167
unstar this property label Biography information for Stephen Twigg more like this
1110302
star this property registered interest false more like this
star this property date less than 2019-04-08more like thismore than 2019-04-08
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of NHS prescriptions for medical cannabis issued in each month since 1 November 2018. more like this
star this property tabling member constituency Liverpool, West Derby more like this
star this property tabling member printed
Stephen Twigg more like this
star this property uin 241990 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-04-11more like thismore than 2019-04-11
star this property answer text <p>NHS England is using extant systems to monitor use of the newly rescheduled unlicensed cannabis-based products for medicinal use in England. In England, these systems monitor the number of items dispensed and associated costs in primary care and the volume of products used and associated cost in secondary care. NHS England Controlled Drug Accountable Officers are also collecting local intelligence in both the National Health Service and independent sector.</p><p> </p><p>Data on the number of items of cannabis-based medicines dispensed in NHS primary care in England from November 2018 to January 2019 has been published by the NHS Business Services Authority. Such data is published three months in arrears, and we expect information for February 2019 to be published shortly.</p><p> </p><p>The published data shows that the following number of items of Nabilone and Sativex (two cannabis-based medicines) were dispensed from November 2018 to January 2019:</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>November 2018</p></td><td><p>December 2018</p></td><td><p>January 2019</p></td></tr><tr><td><p>Nabilone</p></td><td><p>46</p></td><td><p>49</p></td><td><p>44</p></td></tr><tr><td><p>Sativex</p></td><td><p>175</p></td><td><p>181</p></td><td><p>167</p></td></tr></tbody></table><p> </p><p>Data from the NHS Business Services Authority for between November 2018 and January 2019 shows that no prescriptions were dispensed for unlicensed cannabis-based products for medicinal use in primary care in England during this time. We expect data for February 2019 to be available shortly.</p><p> </p><p>Unlike NHS primary care where all dispensed prescriptions are processed centrally, this is not the case for secondary care. This information is collected by a third party and not routinely published.</p><p> </p><p>94 patients have accessed Epidiolex though GW Pharma’s early access programmes ahead of a licensing decision by the European Medicines Agency.</p><p> </p><p>Intelligence from NHS England Controlled Drugs Accountable Officers is that, up until the end to March 2019, one private prescription has been issued for a cannabis-based product for medicinal use in secondary/tertiary care in England.</p><p> </p><p>Import notifications to the Medicines and Healthcare products Regulatory Agency indicate a greater number of supplies. We are therefore cross-checking to ensure that information on the number of prescriptions for cannabis-based products for medicinal use aligns across the different data sources.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property question first answered
less than 2019-04-11T16:56:59.4Zmore like thismore than 2019-04-11T16:56:59.4Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
167
unstar this property label Biography information for Stephen Twigg more like this
1111101
star this property registered interest false more like this
star this property date less than 2019-04-10more like thismore than 2019-04-10
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what recent estimate his Department has made of the number of NHS prescriptions for medicine in which THC is the dominant ingredient. more like this
star this property tabling member constituency Newcastle-under-Lyme more like this
star this property tabling member printed
Paul Farrelly more like this
star this property uin 243361 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-04-17more like thismore than 2019-04-17
star this property answer text <p>The Department has made no estimate of the number of National Health Service prescriptions for cannabis-based products in which delta-9-tetrahydrocannabinol (THC) is the dominant ingredient.</p><p> </p><p>NHS England is using extant systems to monitor use of the newly rescheduled unlicensed cannabis-based products for medicinal use in England. In England, these systems monitor the number of items dispensed and associated costs in primary care and the volume of products used and associated cost in secondary care. NHS England Controlled Drug Accountable Officers are also collecting local intelligence in both the NHS and independent sector.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property question first answered
less than 2019-04-17T11:49:19.043Zmore like thismore than 2019-04-17T11:49:19.043Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property previous answer version
114110
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1436
unstar this property label Biography information for Paul Farrelly more like this
1111106
star this property registered interest false more like this
star this property date less than 2019-04-10more like thismore than 2019-04-10
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what advice has been issued to Clinical Commissioning Groups on the criteria for the prescription of medicinal cannabis. more like this
star this property tabling member constituency Leigh more like this
star this property tabling member printed
Jo Platt more like this
star this property uin 243575 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-04-17more like thismore than 2019-04-17
star this property answer text <p>The Chief Medical Officer and NHS England issued a letter on the 31 October 2018, and a supplementary letter on 20 November 2018, providing guidance to clinicians, the National Health Service and independent organisations following the rescheduling of cannabis-based products for medicinal use on 1 November 2018. This signposts interim guidance issued by the Royal College of Physicians, British Paediatric Neurology Association and Association of British Neurologists.</p><p> </p><p>Furthermore, the National Institute for Health and Care Excellence (NICE), has been commissioned to develop guidelines on the prescribing of cannabis-based medicinal products by October 2019. The guidance will focus on four indications: chronic pain, intractable nausea and vomiting, treatment-resistant epilepsy and spasticity. It will be based on the best available international evidence and produced using NICE’s world-renowned process for delivering such guidelines. This guidance will update and replace the interim guidance.</p><p> </p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property question first answered
less than 2019-04-17T12:26:52.087Zmore like thismore than 2019-04-17T12:26:52.087Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4673
unstar this property label Biography information for Jo Platt more like this
1121479
star this property registered interest false more like this
star this property date less than 2019-04-11more like thismore than 2019-04-11
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, how many NHS prescriptions for medicinal cannabis (a) THC and (b) CBD have been issued in England since December 2018. more like this
star this property tabling member constituency Cardiff Central more like this
star this property tabling member printed
Jo Stevens more like this
star this property uin 244142 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-04-24more like thismore than 2019-04-24
star this property answer text <p>NHS England is using extant systems to monitor use of the newly rescheduled unlicensed cannabis-based products for medicinal use in England. In England, these systems monitor the number of items dispensed and associated costs in primary care and the volume of products used and associated cost in secondary care. NHS England Controlled Drug Accountable Officers are also collecting local intelligence in both the National Health Service and independent sector.</p><p>Data on the number of items of cannabis-based medicines dispensed in NHS primary care in England from December 2018 to January 2019 has been published by the NHS Business Services Authority. Such data is published three months in arrears, and we expect information for February 2019 to be published shortly.</p><p>The published data shows that the following number of items of Nabilone and Sativex (two cannabis-based medicines) were dispensed from December 2018 to January 2019:</p><table><tbody><tr><td><p> </p></td><td><p>December 2018</p></td><td><p>January 2019</p></td></tr><tr><td><p>Nabilone</p></td><td><p>49</p></td><td><p>44</p></td></tr><tr><td><p>Sativex</p></td><td><p>181</p></td><td><p>167</p></td></tr></tbody></table><p><strong> </strong></p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property question first answered
less than 2019-04-24T13:15:40.387Zmore like thismore than 2019-04-24T13:15:40.387Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4425
unstar this property label Biography information for Jo Stevens more like this
1123157
star this property registered interest false more like this
star this property date less than 2019-04-25more like thismore than 2019-04-25
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that patient and health professional organisations are engaged in the Department's working group on medicinal cannabis. more like this
star this property tabling member constituency Carshalton and Wallington more like this
star this property tabling member printed
Tom Brake more like this
star this property uin 247543 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-05-03more like thismore than 2019-05-03
star this property answer text <p>The Department has held a number of engagement events with representatives of patients and health professionals in relation to this policy.</p><p>The Department has also arranged three meetings with stakeholders, ahead of the National Institute for Health and Care Excellence publishing its guidelines on the prescribing of cannabis-based products for medicinal use in October 2019. These meetings are attended by relevant Government departments, public bodies including advisory committees and professional clinical organisations. The purpose of these meetings is to make sure work, already commissioned to implement policy on medicinal cannabis, continues to align in the interim period before the guidelines are issued.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property question first answered
less than 2019-05-03T13:02:14.267Zmore like thismore than 2019-05-03T13:02:14.267Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
151
unstar this property label Biography information for Tom Brake more like this
1123443
star this property registered interest false more like this
star this property date less than 2019-04-26more like thismore than 2019-04-26
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, with reference to his oral contribution of 8 April 2019, Official Report, column 26, how the system of second opinions on the prescribing of medical cannabis oil will be organised; and if he will make a statement. more like this
star this property tabling member constituency Hemel Hempstead more like this
star this property tabling member printed
Sir Mike Penning more like this
star this property uin 247998 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-05-07more like thismore than 2019-05-07
star this property answer text <p>In line with routine clinical practice, patients wishing to seek a second opinion on the National Health Service will be supported to do so. In the first instance, clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support trusts in identifying a suitable NHS specialist for a second opinion.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property grouped question UIN 247999 more like this
star this property question first answered
less than 2019-05-07T16:43:13.763Zmore like thismore than 2019-05-07T16:43:13.763Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1528
unstar this property label Biography information for Sir Mike Penning more like this
1123444
star this property registered interest false more like this
star this property date less than 2019-04-26more like thismore than 2019-04-26
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, with reference to his oral contribution of 8 April 2019, Official Report, column 26, who will be responsible for offering patients a second opinion on prescribing medical cannabis oil. more like this
star this property tabling member constituency Hemel Hempstead more like this
star this property tabling member printed
Sir Mike Penning more like this
star this property uin 247999 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-05-07more like thismore than 2019-05-07
star this property answer text <p>In line with routine clinical practice, patients wishing to seek a second opinion on the National Health Service will be supported to do so. In the first instance, clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support trusts in identifying a suitable NHS specialist for a second opinion.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property grouped question UIN 247998 more like this
star this property question first answered
less than 2019-05-07T16:43:13.81Zmore like thismore than 2019-05-07T16:43:13.81Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1528
unstar this property label Biography information for Sir Mike Penning more like this